Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration

Seoul National University Hospital16,000 enrolled

Overview

this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.

Study Type

OBSERVATIONAL

Enrollment

16,000

Conditions

Coronary Artery Disease Percutaneous Coronary Intervention Dual Antiplatelet Therapy

Interventions

prolonged DAPTDRUG

Dual antiplatelet therapy will be prescribed for more than 12 months

Eligibility

Sex: ALLMin age: 19 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients enrolled in previous RCTs related to the duration of dural antiplatelet agent therapy

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

primary ischemic endpoint

major adverse cardiac events (MACE) defined as the composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis

Time frame: 2 years

primary bleeding endpoints

major bleeding events

Time frame: 2 years

Secondary Outcomes

all-cause death

Time frame: 2 years

cardiac death

Time frame: 2 years

non-cardiac death

Time frame: 2 years

any myocardial infarction

Time frame: 2 years

any stroke

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.